EMA Application withdrawn: Nurzigma (pridopidine hydrochloride) — Prilenia Therapeutics B.V.

View source ↗

Summary

EMA has withdrawn the application for Nurzigma (pridopidine hydrochloride) by Prilenia Therapeutics B.V. for Huntington disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• Nurzigma (pridopidine hydrochloride)

Snippet

Status: Application withdrawn. Therapeutic area: Huntington Disease. MAH: Prilenia Therapeutics B.V.. Decision date: 24/07/2025. Orphan medicine